Enorama Pharma AB (publ) ("Enorama" or "the Company") today announces that the board of directors has decided to postpone the publication of the Company's interim report for the third quarter of 2026 from 18 November 2026 to 27 November 2026.
Publication is postponed for administrative reasons.
CONTACT
Enorama Pharma AB (publ)
Amy Walker, acting CEO
info@enorama.se
Strandvägen 7A, 114 51 Stockholm.
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.